Article Text

Download PDFPDF

Remission in SLE: the duration depends on multiple factors, including the definition
  1. Andrea Doria,
  2. Margherita Zen,
  3. Luca Iaccarino
  1. Rheumatology Unit, Department of Medicine (DIMED), University of Padova, Padova, Italy
  1. Correspondence to Professor Andrea Doria, Rheumatology Unit, Department of Medicine (DIMED), University of Padova, Padova 35128, Italy; adoria{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

We read with great interest the article from Wilhelm et al1 published on Annals of the Rheumatic Diseases. We agree with the authors that remission is an emerging concept in systemic lupus erythematosus (SLE) and that it is very important to find out a definition of remission heralding the best outcome for clinical practice and clinical trials. Although this study, carried out in a very large monocentric cohort of lupus patients, is an important contribution to this topic, its result is a little bit disappointing: indeed, only a minority of lupus patients could maintain a durable remission, which means that, according to this study, remission is not a suitable target for SLE treatment. The percentage of patients with durable remission was so low that the authors did not analyse the effect of remission on disease outcomes such as damage accrual.

In our recent paper,2 we obtained very different results and our patients with durable remission achieved a better outcome compared with unremitted ones. Thus, before considering remission in SLE as a mistaken target, we should critically examine all our results.

Apart from the differences in ethnicity, clinical and serological features between the two cohorts, in Wilhelm's study the authors considered all patients who did not satisfy their definitions of remission at baseline and evaluated the time to the first remission and, thereafter, the time to the first flare. Thus, they evaluated only the first remission period per patient and not the longest period of remission over the follow-up, as we did in our study. This may be misleading since disease activity tends to be higher and the relapsing remitting course more common in the first years from the disease onset.3–8

However, the most important difference between the two studies lies in the definitions of remission and, particularly, the absence of physician global assessment (PGA) in the definitions we used. In Wilhelm's definitions of remission, patients must have both clinical Systemic Lupus Disease Activity Index (cSLEDAI) equal to 0 and PGA score <0.5 in order to be considered as remitted. Remarkably, approximately 40% of patients who did not satisfy the Wilhelm's definitions of remission at study entry had a cSLEDAI score equal to 0 and about 20% had a PGA score <0.5. Thus, the definitions of remission they used were more stringent than our definitions and a discrepancy between cSLEDAI and PGA score could have prevented the fulfilment of the definition of remission in their study.

Wilhelm's study is really very useful since it opens the discussion on a very important question: is it better a stringent definition of remission, only achieved by few patients, or a more liberal one associated with a decrease in damage progression? Thus, before considering disease remission a dead target in SLE treatment, we suggest caution in interpreting and reporting the results of the studies on remission in SLE.


View Abstract


  • Competing interests None declared.

  • Provenance and peer review Not commissioned; internally peer reviewed.

Linked Articles